Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial.

•70 (64.8 %) and 56 (51.9 %) patients remained on BRV for ≥1 and ≥2 years, respectively.•BRV monotherapy had a safety profile consistent with adjunctive therapy.•Median (Q1-Q3) reduction in focal seizure frequency was 56.8 % (11.8–81.1).•Data support the safety of long-term use of BRV (≤200 mg/d) for focal seizures.